跳至主要内容
临床试验/NCT01703416
NCT01703416已完成不适用

CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients Receiving Inhaled Combined Therapy (Corticosteroid/Long Acting ß2-agonist) - RELIEF Study

AstraZeneca0 个研究点目标入组 500 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
500
主要终点
Change from baseline of patient's general health status upon physical evaluation - visual scale

研究概览

简要总结

This is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice the possible correlation between patient perception of the ability to perform morning activities and the physician's assessment during a regular physical exam in patients with Chronic Obstructive Pulmonary Disease (COPD), group C and D.

详细描述

CorRELation between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients receiving inhaled combined therapy (corticosteroid/long acting ß2-agonist) - RELIEF Study

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), group C and D according to GOLD Guidelines, 2011
  • Receive inhaled combined therapy for COPD (inhaled corticosteroid / long acting ß2-agonist); this treatment should have been initiated for at least one month before entering the study
  • Current or past smokers, of at least 10 pack years

排除标准

  • History of exacerbation of COPD symptoms within the last month before visit 1, inclusive.
  • History of asthma or allergic rhinitis.
  • History of lung carcinoma or any other respiratory condition that may limit the airflow circulation.

结局指标

主要结局

Change from baseline of patient's general health status upon physical evaluation - visual scale

时间窗: Baseline and 3 months

Change from baseline in CDLM (Capacity of Daily Living during the Morning) questionnaire.

时间窗: Baseline and 3 months

次要结局

  • Patient adherence to treatment (by using visual 5 point scale)(up to 3 months)
  • Number of unscheduled visit (exacerbations, emergency visits)(up to 3 months)
  • Age (years), gender (male/female), weight (kg), height (cm), place of origin (urban/rural)(Day 0 (visit 1))
  • Number of daily walking steps (by using pedometers)(up to 3 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

相似试验